Skip to Content

Manageable safety profile and promising efficacy in heavily pretreated patients with R/R Non-Hodgin Lymphoma

In this MEDtalk, Jean Marie Michot, MD, Paris, presents insights from poster S216  at EHA22, where a Cereblon E3 Ligase Modulator agent in monotherapy demostrate a showed a manageable safety profile and promising efficacy in heavily pretreated patients with R/R Non-Hodgin Lymphoma.

Jean-Marie Michot

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top